The Economic Times
English EditionEnglish Editionहिंदी संस्करण
| 27 April, 2021, 12:02 AM IST | E-Paper
Search
+

    The ₹623.75 billion question: How soon can India vaccinate a enough of the population to make a difference?

    Synopsis

    Both Serum Institute of India (SII) and Bharat Biotech have announced the price of their vaccine to be supplied under the liberalised scheme. SII has stated that it will supply at ₹500 a dose to central and state government, and ₹600 a dose to the private sector. Bharat Biotech has announced that it will continue to supply vaccine to GoI at ₹150 a dose, but will charge ₹600 a dose to state governments, and ₹1,200 a dose to the private sector.

    With the accelerated Phase 3 strategy of Covid-19 vaccination to start from May 1, allowing persons of 18 years and above to vaccinated, an estimated 841.95 million out of India’s population of 1,333 million will be eligible for anti-Covid shots. GoI has reiterated that the cost of vaccination for priority sections — healthcare workers, frontline workers and those above 45 —will continue to be borne by it. However, under the liberalised scheme,
    Share This Article
    • GIFT ARTICLE
    • FONT SIZE
    • SAVE
    • PRINT
    • COMMENT

    Sign in to read the full article

    You’ve got this Prime Story as a Free Gift

    Special Offer on ET Prime

    Subscribe to ET Prime - Get Flat 20% Off

    View Plans

    Special Offer on ET Prime

    Subscribe to ET Prime - Get Flat 20% Off

    View Plans

    Special Offer on ET Prime

    Subscribe to ET Prime - Get Flat 20% Off

    View Plans

    Why ?

    • Sharp Insight-rich, Indepth stories across 20+ sectors

    • Access the exclusive Economic Times stories, Editorial and Expert opinion

    • Clean experience with
      Minimal Ads
    • Comment & Engage with ET Prime community
    • Exclusive invites to Virtual Events with Industry Leaders
    • A trusted team of Journalists & Analysts who can best filter signal from noise
    The Economic Times